Search Within

Robert Motzer

Formats
  1. Journal Article (609)
  2. Meeting Abstract (577)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (6)
  6. Correspondence (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1246)
  2. Genitourinary Oncology Service (1246)
  3. Solid Tumor Oncology Division (1246)
  4. Surgery (290)
  5. Urology (281)
  6. Survivorship Research (253)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (29)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (447)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (450)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1246)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sunitinib vs. interferon-alpha (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation
    Meeting Abstract

    Remak, E.; Brown, R.; Negrier, S.; Motzer, R. J.; Kim, S. T.; Charbonneau, C.
    Value in Health (2007)

    Fulltext@MSK | Save
  • Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Redman, B. G.; Hudes, G. R.; Kondagunta, G. V.; Patel, P. H.; Kim, S. T.; Chen, I.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Economic evaluation of sunitinib vs. interferon-alfa (IFN-alpha) in first-line metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Negrier, S.; Remak, E.; Brown, R.; Kim, S. T.; Charbonneau, C.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated efficacy and safety results and further analysis of prognostic factors
    Meeting Abstract

    Motzer, R. J.; Michaelson, M. D.; Hutson, T. E.; Tomczak, P.; Bukowski, R. M.; Rixe, O.; Negrier, S.; Kim, S. T.; Chen, I.; Figlin, R. A.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib plus interferon-alfa in the first-line treatment for metastatic renal cell carcinoma (mRCC): Results of a dose-finding study
    Meeting Abstract

    Kondagunta, G. V.; Hudes, G.; Figlin, R.; Wilding, G.; Hariharan, S.; Kempin, S.; Fayyad, R.; Hoosen, S.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Houk, B. E.; Bello, C. L.; Michaelson, M. D.; Bukowski, R. M.; Redman, B.; Hudes, G. R.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    George, D. J.; Michaelson, M. D.; Rosenberg, J. E.; Redman, B. G.; Hudes, G. R.; Bukowski, R. M.; Kim, S. T.; Chen, I.; Wilding, G.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) and kidney cancer-related symptoms in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib versus interferon (IFN)-alfa: results for European and US subsample analyses in a randomized, multinational phase III trial
    Meeting Abstract

    Cella, D.; Li, J. Z.; Bushmakin, A. G.; Cappelleri, J. C.; Kim, S. T.; Chen, I.; Charbonneau, C.; Motzer, R. J.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • Effects of sunitinib versus interferon-alfa in health-related quality of life in patients with metastatic renal cell carcinoma (MRCC): Results from a randomized multinational phase III trial
    Meeting Abstract

    Cello, D.; Li, J.; Cappelleri, J. C.; Bushmakin, A.; Kim, S. T.; Chen, I.; Motzer, R. J.
    European Urology, Supplements (2007)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQOL) and kidney cancer-related symptoms in patients with metastatic renal cell carcinoma (MRCC) treated with sunitinib versus interferon (IFN)-alfa in a randomised, multinational phase III trial: Results for European and US subsample analyses
    Meeting Abstract

    Cella, D.; Li, J. Z.; Bushmakin, A. G.; Cappelleri, J. C.; Kim, S. T.; Chen, F.; Charbonneau, C.; Motzer, R. J.
    Value in Health (2007)

    Fulltext@MSK | Save